The endocannabinoid system, or ECS , is a key regulator that plays a very important role in the functioning of almost our entire physiological system.

For a very long time, the endocannabinoid system was overlooked as a possible target for therapeutic intervention, mainly due to the lack of knowledge about it and the association of this system with diseases.

However, with the growing interest in medical marijuana, cannabinoids and, above all, cannabidiol (CBD) and cannabidiol acid (CBDA), many medical researchers are beginning to take an interest in the endocannabinoid system.

There is a growing body of convincing evidence that supports the theory of clinical endocannabinoid deficiency, primarily in conditions such as migraine, fibromyalgia and irritable bowel syndrome.

Given the large number of diseases with endocannabinoid anomalies, including epilepsy, cancer and numerous neurodegenerative diseases, this area is sure to be the main focus of research in the future.

ECS

Recently, it has been discovered that in addition to phytocannabinoids derived from cannabis, many other natural compounds also affect the functioning of the endocannabinoid system.

The ECS is mainly made up of two receptors (known as CB1 and CB2), although new research suggests that they may also affect other receptor cells. The ECS is usually stimulated by endocannabinoids such as anandamide or 2-AG, which are naturally produced by our body. However, if plant-based phytocannabinoids such as CBD or CBDa are present, they also interact with this system by binding to CB1 and/or CB2 receptors, causing many beneficial therapeutic effects.